{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:15:36Z","timestamp":1790946936082,"version":"4.1.0"},"reference-count":197,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.gastrohep.2016.05.003","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T19:59:45Z","timestamp":1467057585000},"page":"697-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["IV Conferencia Espa\u00f1ola de Consenso sobre el tratamiento de la infecci\u00f3n por Helicobacter pylori"],"prefix":"10.1016","volume":"39","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuadrado-Lav\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Ignasi","family":"Elizalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Gene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00edn de Argila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferm\u00edn","family":"Mearin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"P\u00e9rez-Aisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"P\u00e9rez-Trallero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2016.05.003_bib0990","first-page":"777","article-title":"Helicobacter pylori infection. The Spanish consensus report","volume":"91","author":"Sainz","year":"1999","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib0995","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7753(00)71237-1","article-title":"Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference","volume":"114","author":"Gisbert","year":"2000","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1000","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4321\/S1130-01082005000500007","article-title":"Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference","volume":"97","author":"Mones","year":"2005","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1157\/13078424","article-title":"Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference","volume":"125","author":"Gisbert","year":"2005","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.gastrohep.2013.01.011","article-title":"III Spanish Consensus Conference on Helicobacter pylori infection","volume":"36","author":"Gisbert","year":"2013","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1015","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1157\/13117903","article-title":"How can we find, design, evaluate and use clinical practice guidelines?","volume":"31","author":"Gisbert","year":"2008","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","article-title":"Experimental Study of Group Opinion-Delphi Method","volume":"1","author":"Dalkey","year":"1969","journal-title":"Features"},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1155\/2014\/680829","article-title":"Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines","volume":"28","author":"Singh","year":"2014","journal-title":"Can J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1040","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/jac\/dkv155","article-title":"Systematic review and meta-analysis: Susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection","volume":"70","author":"Lopez-Gongora","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1045","first-page":"2447","article-title":"Systematic review: Third-line susceptibility guided treatment for Helicobacter pylori infection","volume":"70","author":"Puig","year":"2015","journal-title":"Ther Adv Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.gastrohep.2010.10.013","article-title":"Rescue therapy after Helicobacter pylori eradication failure","volume":"34","author":"Gisbert","year":"2011","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00042737-199701000-00002","article-title":"Current European concepts in the management of Helicobacter pylori infection\u2014the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG)","volume":"9","author":"Malfertheiner","year":"1997","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","article-title":"Current concepts in the management of Helicobacter pylori infection\u2014the Maastricht 2-2000 Consensus Report","volume":"16","author":"Malfertheiner","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1070","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.gtc.2015.05.004","article-title":"Practical aspects in choosing a Helicobacter pylori therapy","volume":"44","author":"Molina-Infante","year":"2015","journal-title":"Gastroenterol Clin North Am."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2016.05.003_bib1085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0210-5705(15)30018-2","article-title":"Helicobacter pylori-associated diseases","volume":"38","author":"Gisbert","year":"2015","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1095","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2011.04887.x","article-title":"Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.gastrohep.2013.02.006","article-title":"Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)","volume":"36","author":"Molina-Infante","year":"2013","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1105","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkv089","article-title":"First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: An open-label, randomized, multicentre clinical trial","volume":"70","author":"Cuadrado-Lavin","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1110","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/MEG.0000000000000197","article-title":"Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions","volume":"26","author":"Martos","year":"2014","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/apt.13069","article-title":"Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: The OPTRICON study","volume":"41","author":"Molina-Infante","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/hel.12187","article-title":"Helicobacter pylori infection in children. Antimicrobial resistance and treatment response","volume":"20","author":"Montes","year":"2015","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000435949","article-title":"Prevalence of primary resistance of Helicobacter pylori to clarithromycin and levofloxacin in Southern Spain","volume":"92","author":"Navarro-Jarabo","year":"2015","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1523-5378.2012.00947.x","article-title":"Nonbismuth quadruple (concomitant) therapy: Empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains","volume":"17","author":"Molina-Infante","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1140","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.03.050","article-title":"Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance","volume":"145","author":"Molina-Infante","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2013-304820","article-title":"Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice","volume":"63","author":"McNicholl","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1150","first-page":"A65","article-title":"Non bismuth quadruple \u2018concomitant\u2019 therapies in the eradication of Helicobacter pylori: Standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice","volume":"3","author":"McNicholl","year":"2015","journal-title":"United European Gastroenterol J."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00365521.2015.1079646","article-title":"Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: A Greek randomized prospective study","volume":"51","author":"Apostolopoulos","year":"2016","journal-title":"Scand J Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2016.05.003_bib1160","first-page":"80","article-title":"A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high clarithromycin resistance area","volume":"19","author":"Georgopoulos","year":"2014","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/hel.12062","article-title":"Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area","volume":"18","author":"Georgopoulos","year":"2013","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study","volume":"37","author":"Zullo","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"Pt 5","key":"10.1016\/j.gastrohep.2016.05.003_bib1175","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/jmm.0.072322-0","article-title":"Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: A prospective randomized study","volume":"63","author":"De Francesco","year":"2014","journal-title":"J Med Microbiol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.09.030","article-title":"Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection","volume":"8","author":"Wu","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1185","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1128\/AAC.02922-14","article-title":"Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection","volume":"58","author":"Hsu","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4292\/wjgpt.v3.i1.1","article-title":"Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan","volume":"3","author":"Yanai","year":"2012","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1195","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1523-5378.2011.00823.x","article-title":"A new modified concomitant therapy for Helicobacter pylori eradication in Turkey","volume":"16","author":"Toros","year":"2011","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/hel.12034","article-title":"Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: A randomized pilot study","volume":"18","author":"Lim","year":"2013","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1205","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/jgh.12983","article-title":"Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial","volume":"30","author":"Heo","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: A randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hel.12231","article-title":"Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance","volume":"21","author":"Cosme","year":"2016","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1220","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1225","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jgh.12397","article-title":"Meta-analysis: Is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?","volume":"28","author":"Yoon","year":"2013","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1230","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1097\/MJT.0000000000000191","article-title":"Sequential therapy or standard triple therapy for Helicobacter pylori infection: An updated systematic review","volume":"23","author":"Feng","year":"2016","journal-title":"Am J Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1235","article-title":"Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial","author":"Liou","year":"2015","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1240","unstructured":"McNicholl AG, Gisbert JP. Non-bismuth quadruple concomitant treatment: Systematic review and meta-analysis. Am J Gastroenterol. En prensa. 2016."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MCG.0b013e3181c8a1a3","article-title":"Sequential therapy for Helicobacter pylori eradication: A critical review","volume":"44","author":"Gisbert","year":"2010","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hel.12240","article-title":"Sequential therapy for Helicobacter pylori infection in treatment-naive children","volume":"21","author":"Schwarzer","year":"2015","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","article-title":"Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days","volume":"16","author":"Hsu","year":"2011","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/hel.12113","article-title":"Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate","volume":"19","author":"Wu","year":"2014","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1265","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.3748\/wjg.v21.i36.10435","article-title":"Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial","volume":"21","author":"Chen","year":"2015","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1270","doi-asserted-by":"crossref","first-page":"e0124199","DOI":"10.1371\/journal.pone.0124199","article-title":"The primary resistance of Helicobacter pylori in Taiwan after the National policy to restrict antibiotic consumption and its relation to virulence factors\u2014A nationwide study","volume":"10","author":"Liou","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hel.12017","article-title":"Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: A prospective randomized trial","volume":"18","author":"Sardarian","year":"2013","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hel.12202","article-title":"Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication: A randomized clinical trial","volume":"20","author":"Metanat","year":"2015","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1285","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jgh.12518","article-title":"Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy","volume":"29","author":"Oh","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1756283X11432492","article-title":"The challenge of Helicobacter pylori resistance to antibiotics: The comeback of bismuth-based quadruple therapy","volume":"5","author":"Megraud","year":"2012","journal-title":"Therap Adv Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/1751-2980.12034","article-title":"Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection","volume":"14","author":"Liu","year":"2013","journal-title":"J Dig Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1300","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: A meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1315","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1320","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1523-5378.2012.00962.x","article-title":"Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: A pilot study in US Hispanics","volume":"17","author":"Salazar","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1325","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","article-title":"How to effectively use bismuth quadruple therapy: The good, the bad, and the ugly","volume":"44","author":"Graham","year":"2015","journal-title":"Gastroenterol Clin North Am."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1330","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","article-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","volume":"64","author":"Zhang","year":"2015","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CEG.S25419","article-title":"Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori","volume":"5","author":"Gisbert","year":"2012","journal-title":"Clin Exp Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1523-5378.1998.08019.x","article-title":"Amoxicillin\/metronidazole\/omeprazole\/clarithromycin: A new, short quadruple therapy for Helicobacter pylori eradication","volume":"3","author":"Treiber","year":"1998","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1345","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s005350050150","article-title":"A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate","volume":"33","author":"Okada","year":"1998","journal-title":"J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinte.162.2.153","article-title":"Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: A randomized controlled trial (MACLOR study)","volume":"162","author":"Treiber","year":"2002","journal-title":"Arch Intern Med."},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2016.05.003_bib1355","first-page":"135","article-title":"Effectiveness of 5-day and 7-day quadruple \u2018concomitant\u2019 therapy regimen for Helicobacter pylori infection in Korea","volume":"16","author":"Kwon","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1360","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1523-5378.2012.00953.x","article-title":"Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand","volume":"17","author":"Kongchayanun","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1365","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2036.2011.04770.x","article-title":"Review article: Non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1370","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","article-title":"Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance","volume":"20","author":"Molina-Infante","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1375","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1380","first-page":"CD008337","article-title":"Optimum duration of regimens for Helicobacter pylori eradication","volume":"12","author":"Yuan","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1385","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1523-5378.2011.00857.x","article-title":"Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: A randomized trial of 10 and 14 days","volume":"16","author":"Dore","year":"2011","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1390","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","volume":"98","author":"Laine","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1395","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.7314\/APJCP.2015.16.14.6089","article-title":"Seven-day bismuth-based quadruple therapy as an initial treatment for Helicobacter pylori infection in a high metronidazole resistant area","volume":"16","author":"Vilaichone","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1400","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1365-2036.2000.00844.x","article-title":"Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori","volume":"14","author":"Gisbert","year":"2000","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1405","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02687.x","article-title":"Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin","volume":"22","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1410","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.dld.2009.06.007","article-title":"Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin","volume":"42","author":"Gisbert","year":"2010","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1415","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0025-7753(01)71738-1","article-title":"Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review","volume":"116","author":"Gisbert","year":"2001","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1420","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10620-005-2549-1","article-title":"High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin","volume":"50","author":"Rodriguez-Torres","year":"2005","journal-title":"Dig Dis Sci."},{"issue":"1 Pt 2","key":"10.1016\/j.gastrohep.2016.05.003_bib1425","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1746.2006.04171.x","article-title":"Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection","volume":"21","author":"Matsushima","year":"2006","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1430","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1435","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","article-title":"Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy","volume":"60","author":"Gisbert","year":"2015","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1440","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCG.0b013e3182702dbc","article-title":"The use of probiotics in Helicobacter pylori eradication therapy","volume":"47","author":"Medeiros","year":"2013","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1450","first-page":"217","article-title":"Probiotics and Helicobacter pylori infection","volume":"14","author":"Praitano","year":"2012","journal-title":"Medicina Universitaria."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2036.2006.03179.x","article-title":"Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy","volume":"25","author":"Tong","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1460","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2036.2009.03934.x","article-title":"Meta-analysis: Efficacy of bovine lactoferrin in Helicobacter pylori eradication","volume":"29","author":"Sachdeva","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1465","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1523-5378.2009.00666.x","article-title":"Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy","volume":"14","author":"Zou","year":"2009","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MEG.0b013e32830d0eff","article-title":"Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials","volume":"21","author":"Sachdeva","year":"2009","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1475","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2036.2010.04457.x","article-title":"Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment","volume":"32","author":"Szajewska","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MCG.0b013e318266f6cf","article-title":"Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy","volume":"47","author":"Wang","year":"2013","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1485","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4321\/S1130-01082013000800002","article-title":"Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis","volume":"105","author":"Zheng","year":"2013","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1490","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.3748\/wjg.v20.i47.18013","article-title":"Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy","volume":"20","author":"Zhu","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1495","doi-asserted-by":"crossref","first-page":"e111030","DOI":"10.1371\/journal.pone.0111030","article-title":"The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis","volume":"9","author":"Dang","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1500","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00431-013-2220-3","article-title":"Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children","volume":"173","author":"Li","year":"2014","journal-title":"Eur J Pediatr."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1505","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.3748\/wjg.v21.i14.4345","article-title":"Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1510","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-230X-13-56","article-title":"Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: A prospective, randomized, double-blind, placebo-controlled study","volume":"13","author":"Navarro-Rodriguez","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1515","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/hel.12047","article-title":"The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: A randomized placebo-controlled triple-blind study","volume":"18","author":"Shavakhi","year":"2013","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1520","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1097\/MD.0000000000000685","article-title":"Probiotics for standard triple Helicobacter pylori eradication: A randomized, double-blind, placebo-controlled trial","volume":"94","author":"Hauser","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1525","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4321\/S1130-01082013000800001","article-title":"Probiotics for Helicobacter pylori eradication therapy: Not ready for prime time","volume":"105","author":"Molina-Infante","year":"2013","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1530","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656566.2013.782286","article-title":"A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication)","volume":"14","author":"Marin","year":"2013","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1535","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","article-title":"Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1540","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-analysis","volume":"101","author":"Saad","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1545","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MCG.0b013e318254ebdd","article-title":"Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: Time trends in a Spanish multicenter study of 1000 patients","volume":"47","author":"Gisbert","year":"2013","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1550","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1555","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00508-007-0807-2","article-title":"High eradication rate of H. pylori with moxifloxacin-based treatment: A randomized controlled trial","volume":"119","author":"Bago","year":"2007","journal-title":"Wien Klin Wochenschr."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1560","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3748\/wjg.v16.i34.4357","article-title":"Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication","volume":"16","author":"Gao","year":"2010","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1565","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2362.2008.01951.x","article-title":"Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures","volume":"38","author":"Hsu","year":"2008","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1570","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2036.2007.03452.x","article-title":"Clinical trial: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection","volume":"26","author":"Yee","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1575","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/apt.13128","article-title":"Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1580","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/apt.13177","article-title":"Letter: Bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance","volume":"41","author":"Graham","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1585","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkr410","article-title":"Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain","volume":"67","author":"Cuadrado-Lavin","year":"2012","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1590","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/apt.12808","article-title":"Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori","volume":"40","author":"Delchier","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"issue":"5 Suppl. 1","key":"10.1016\/j.gastrohep.2016.05.003_bib1595","article-title":"Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple \u2018sequential\u2019 or \u2018concomitant\u2019 treatment to eradicate H. pylori infection","volume":"146","author":"Gisbert","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1600","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1523-5378.2012.00945.x","article-title":"Helicobacter pylori infection: Sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate","volume":"17","author":"Manfredi","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1605","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","article-title":"Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance","volume":"39","author":"Perna","year":"2007","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1610","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.dld.2009.12.007","article-title":"Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice","volume":"42","author":"Pontone","year":"2010","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1615","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/14750708.3.2.251","article-title":"Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: A pilot study","volume":"3","author":"Zullo","year":"2006","journal-title":"Therapy."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1620","doi-asserted-by":"crossref","first-page":"605","DOI":"10.5009\/gnl13303","article-title":"The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea","volume":"8","author":"Chung","year":"2014","journal-title":"Gut Liver."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1625","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.3748\/wjg.v20.i22.6932","article-title":"Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea","volume":"20","author":"Kang","year":"2014","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1630","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.dld.2014.10.009","article-title":"Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments","volume":"47","author":"Gisbert","year":"2015","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1635","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1523-5378.2012.00960.x","article-title":"The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin\/amoxicillin\/proton-pump inhibitor treatment\u2014a pilot study","volume":"17","author":"Chuah","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1640","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.dld.2008.09.013","article-title":"Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication","volume":"41","author":"Di Caro","year":"2009","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1645","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrgastro.2010.131","article-title":"Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication","volume":"7","author":"Malfertheiner","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1650","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2013-306120","article-title":"Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: An open label, randomised, crossover trial","volume":"63","author":"Liu","year":"2014","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1655","article-title":"Efficacy of the 14-day quadruple regimen (proton pump inhibitor, bismuth, tetracycline and metronidazole) as a rescue therapy after failure with the 10-days sequential therapy for eradication of Helicobacter pylori","volume":"138","author":"Kim","year":"2010","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1660","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/hel.12085","article-title":"Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy","volume":"19","author":"Hsu","year":"2014","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1665","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1523-5378.2012.00946.x","article-title":"A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure","volume":"17","author":"Fakheri","year":"2012","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1670","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1675","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2005.02522.x","article-title":"A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses","volume":"22","author":"Gatta","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1680","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1572-0241.2006.00457.x","article-title":"Third-line rescue therapy with levofloxacin after two H. pylori treatment failures","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1685","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1365-2036.2006.03149.x","article-title":"Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures","volume":"24","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1690","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ajg.2008.87","article-title":"Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen","volume":"104","author":"Rokkas","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1695","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1365-2036.2012.05117.x","article-title":"Letter: Third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1700","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","article-title":"Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: A meta-analysis","volume":"122","author":"Li","year":"2010","journal-title":"Wien Klin Wochenschr."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1705","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","article-title":"Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin","volume":"53","author":"Furuta","year":"2014","journal-title":"Intern Med."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1710","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/AAC.01552-08","article-title":"Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1715","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12089","article-title":"Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations","volume":"36","author":"Tay","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1720","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10620-013-2900-x","article-title":"Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection","volume":"59","author":"Gisbert","year":"2014","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1725","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1523-5378.2005.00324.x","article-title":"Helicobacter pylori \u2018rescue\u2019 therapy after failure of two eradication treatments","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1730","first-page":"1134","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China","volume":"25","author":"Lu","year":"2013","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1735","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1740","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-200010000-00007","article-title":"Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: Preliminary experience","volume":"31","author":"Bock","year":"2000","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1745","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2036.2001.00909.x","article-title":"Rifabutin-based Helicobacter pylori eradication \u2018rescue therapy\u2019","volume":"15","author":"Canducci","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1750","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1523-5378.2007.00588.x","article-title":"One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"13","author":"Miehlke","year":"2008","journal-title":"Helicobacter."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1755","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2036.2000.00719.x","article-title":"Rifabutin-based \u2018rescue therapy\u2019 for Helicobacter pylori infected patients after failure of standard regimens","volume":"14","author":"Perri","year":"2000","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1760","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1365-2036.2007.03531.x","article-title":"The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice","volume":"26","author":"Van der Poorten","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1765","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1155\/2010\/637908","article-title":"Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection","volume":"24","author":"Van Zanten","year":"2010","journal-title":"Can J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1770","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","article-title":"Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1775","doi-asserted-by":"crossref","first-page":"367","DOI":"10.15403\/jgld.2014.1121.234.qrth","article-title":"Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: Comparison between two tetracycline-based regimens","volume":"23","author":"Ierardi","year":"2014","journal-title":"J Gastrointestin Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1780","first-page":"693","article-title":"Helicobacter pylori and duodenal ulcer: A causal relation or mere association?","volume":"197","author":"Gisbert","year":"1997","journal-title":"Rev Clin Esp."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1785","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02418.x","article-title":"Systematic review and meta-analysis: Is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1790","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1365-2036.2002.01260.x","article-title":"Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: A multicentre double-blind placebo-controlled trial","volume":"16","author":"Colin","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1795","first-page":"1731","article-title":"One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing","volume":"50","author":"Hsu","year":"2003","journal-title":"Hepatogastroenterology."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1800","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2036.1997.80252000.x","article-title":"One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers","volume":"11","author":"Labenz","year":"1997","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1805","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1590-8658(02)00006-3","article-title":"Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial","volume":"35","author":"Marzio","year":"2003","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1810","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2036.2001.01020.x","article-title":"Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?","volume":"15","author":"Tepes","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1815","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/00042737-200112000-00009","article-title":"One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease","volume":"13","author":"Tulassay","year":"2001","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1820","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10620-006-9522-5","article-title":"One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients","volume":"52","author":"Subei","year":"2007","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1825","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3164\/jcbn.12-15","article-title":"Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: Differences of gastric ulcers and duodenal ulcers","volume":"51","author":"Takeuchi","year":"2012","journal-title":"J Clin Biochem Nutr."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1830","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1572-0241.1998.00333.x","article-title":"The impact of Helicobacter pylori eradication on peptic ulcer healing","volume":"93","author":"Treiber","year":"1998","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1835","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1046\/j.1365-2036.2001.01109.x","article-title":"A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer","volume":"15","author":"Leodolter","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1840","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2000.00803.x","article-title":"Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage","volume":"14","author":"Lai","year":"2000","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1845","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2036.2003.01402.x","article-title":"Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study","volume":"17","author":"Higuchi","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1850","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MEG.0b013e3282f427ac","article-title":"Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients","volume":"20","author":"Tulassay","year":"2008","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1855","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/00365521.2003.11800649","article-title":"Helicobacter pylori and bleeding peptic ulcer: What is the prevalence of the infection in patients with this complication?","volume":"38","author":"Gisbert","year":"2003","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1860","first-page":"CD004062","article-title":"H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer","volume":"2","author":"Gisbert","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1865","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2004.01898.x","article-title":"Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer","volume":"19","author":"Gisbert","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1870","first-page":"47","article-title":"Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori","volume":"29","author":"Amendola","year":"1999","journal-title":"Acta Gastroenterol Latinoam."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1875","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1572-0241.2003.07682.x","article-title":"Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer","volume":"98","author":"Arkkila","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1880","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2036.2001.00992.x","article-title":"Occurrence and relapse of bleeding from duodenal ulcer: Respective roles of acid secretion and Helicobacter pylori infection","volume":"15","author":"Capurso","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1885","first-page":"161","article-title":"Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: The prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence","volume":"112","author":"Gisbert","year":"1999","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1890","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3109\/00365529309098288","article-title":"Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease","volume":"28","author":"Graham","year":"1993","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1895","first-page":"139","article-title":"The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer","volume":"29","author":"Horvat","year":"2005","journal-title":"Coll Antropol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1900","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0016-5107(95)70267-9","article-title":"Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage","volume":"41","author":"Jaspersen","year":"1995","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1905","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02347506","article-title":"Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study","volume":"30","author":"Jaspersen","year":"1995","journal-title":"J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1910","first-page":"183","article-title":"Comparative amoxicillin Azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer","volume":"47","author":"Krizman","year":"1997","journal-title":"Acta Pharmaceutica."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1915","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000201117","article-title":"Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse","volume":"55","author":"Labenz","year":"1994","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1920","first-page":"2225","article-title":"Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage\u2014a long-term randomized, controlled study","volume":"95","author":"Lai","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1925","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/archinte.163.17.2020","article-title":"Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: A 5-year prospective, randomized, controlled study","volume":"163","author":"Liu","year":"2003","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1930","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1572-0241.1998.00278.x","article-title":"Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: A long-term follow-up study","volume":"93","author":"Macri","year":"1998","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1935","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-200103000-00008","article-title":"The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer","volume":"32","author":"Pellicano","year":"2001","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1940","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0016-5107(97)70114-7","article-title":"Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding","volume":"46","author":"Riemann","year":"1997","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5107(95)70266-0","article-title":"Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease","volume":"41","author":"Rokkas","year":"1995","journal-title":"Gastrointest Endosc."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1950","first-page":"1549","article-title":"Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: Prospective nonrandomized trial on 125 patients","volume":"91","author":"Santander","year":"1996","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1955","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1023\/A:1018816729449","article-title":"One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding","volume":"42","author":"Sung","year":"1997","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1960","first-page":"59","article-title":"Eradication of Helicobacter pylori reduces the possibility of rebleeding in duodenal ulcer disease","volume":"21","author":"Vcev","year":"1996","journal-title":"Acta Fam Med Flum."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1965","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00042737-200012070-00003","article-title":"Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage","volume":"12","author":"Vergara","year":"2000","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2016.05.003_bib1970","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ajg.2012.132","article-title":"Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol."}],"updated-by":[{"DOI":"10.1016\/j.gastre.2017.04.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000}},{"DOI":"10.1016\/j.gastrohep.2017.02.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000}}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570516300589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570516300589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T08:21:11Z","timestamp":1656750071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570516300589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":197,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0210570516300589"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2016.05.003","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IV Conferencia Espa\u00f1ola de Consenso sobre el tratamiento de la infecci\u00f3n por Helicobacter pylori","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2016.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U., AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}